Malaysian Genomics Resource Centre Bhd (XKLS:0155) Piotroski F-Score: 7 (As of Jun. 26, 2026) — 75% Above Median


XKLS:0155 Malaysian Genomics Resource Centre Bhd XKLS:0155
47 GF Score
Price RM0.27
GF Value RM0.30
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Malaysian Genomics Resource Centre Bhd Piotroski F-Score?

Malaysian Genomics Resource Centre Bhd XKLS:0155 47 Piotroski F-Score is 7 as of Jun. 26, 2026, which is 75% above its 10-year median of 4.00. GuruFocus rates XKLS:0155 with a GF Score™ of 47/100 and a GF Value™ of RM0.30 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Malaysian Genomics Resource Centre Bhd ranks better than 93.84% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Malaysian Genomics Resource Centre Bhd has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Malaysian Genomics Resource Centre Bhd's Piotroski F-Score or its related term are showing as below:

XKLS:0155' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 8
Current: 7

During the past 13 years, the highest Piotroski F-Score of Malaysian Genomics Resource Centre Bhd was 8. The lowest was 1. And the median was 4.

Malaysian Genomics Resource Centre Bhd  (XKLS:0155) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Malaysian Genomics Resource Centre Bhd Piotroski F-Score Related Terms


Malaysian Genomics Resource Centre Bhd Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Malaysian Genomics Resource Centre Bhd's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Malaysian Genomics Resource Centre Bhd Piotroski F-Score Chart

Malaysian Genomics Resource Centre Bhd Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 N/A N/A 1.00 7.00

Malaysian Genomics Resource Centre Bhd Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 6.00 7.00 7.00 7.00

XKLS:0155 vs TMO, DHR, IDXX: Piotroski F-Score Comparison

For the Diagnostics & Research subindustry, Malaysian Genomics Resource Centre Bhd's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Malaysian Genomics Resource Centre Bhd Piotroski F-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Malaysian Genomics Resource Centre Bhd's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Malaysian Genomics Resource Centre Bhd's Piotroski F-Score falls into.


XKLS:0155
47GF Score
Malaysian Genomics Resource Centre Bhd XKLS:0155
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -0.37 + 0.389 + -1.653 + 1.14 = RM-0.49 Mil.
Cash Flow from Operations was -0.226 + 0.573 + 0.513 + 0.098 = RM0.96 Mil.
Revenue was 1.796 + 2.484 + 2.394 + 2.654 = RM9.33 Mil.
Gross Profit was 1.188 + 1.628 + 1.449 + 2.386 = RM6.65 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(21.499 + 20.724 + 20.696 + 18.709 + 21.396) / 5 = RM20.6048 Mil.
Total Assets at the begining of this year (Mar25) was RM21.50 Mil.
Long-Term Debt & Capital Lease Obligation was RM0.84 Mil.
Total Current Assets was RM12.58 Mil.
Total Current Liabilities was RM2.27 Mil.
Net Income was -1.333 + -0.928 + -0.494 + -0.748 = RM-3.50 Mil.

Revenue was 1.303 + 1.401 + 1.309 + 1.349 = RM5.36 Mil.
Gross Profit was 0.537 + 0.887 + 1.052 + 0.94 = RM3.42 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(24.685 + 23.862 + 22.841 + 22.355 + 21.499) / 5 = RM23.0484 Mil.
Total Assets at the begining of last year (Mar24) was RM24.69 Mil.
Long-Term Debt & Capital Lease Obligation was RM1.15 Mil.
Total Current Assets was RM11.11 Mil.
Total Current Liabilities was RM3.60 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Malaysian Genomics Resource Centre Bhd's current Net Income (TTM) was -0.49. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Malaysian Genomics Resource Centre Bhd's current Cash Flow from Operations (TTM) was 0.96. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-0.494/21.499
=-0.02297781

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-3.503/24.685
=-0.14190804

Malaysian Genomics Resource Centre Bhd's return on assets of this year was -0.02297781. Malaysian Genomics Resource Centre Bhd's return on assets of last year was -0.14190804. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Malaysian Genomics Resource Centre Bhd's current Net Income (TTM) was -0.49. Malaysian Genomics Resource Centre Bhd's current Cash Flow from Operations (TTM) was 0.96. ==> 0.96 > -0.49 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0.842/20.6048
=0.04086426

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=1.151/23.0484
=0.04993839

Malaysian Genomics Resource Centre Bhd's gearing of this year was 0.04086426. Malaysian Genomics Resource Centre Bhd's gearing of last year was 0.04993839. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=12.575/2.273
=5.53233612

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=11.106/3.602
=3.08328706

Malaysian Genomics Resource Centre Bhd's current ratio of this year was 5.53233612. Malaysian Genomics Resource Centre Bhd's current ratio of last year was 3.08328706. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Malaysian Genomics Resource Centre Bhd's number of shares in issue this year was 144.528. Malaysian Genomics Resource Centre Bhd's number of shares in issue last year was 137.21. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=6.651/9.328
=0.71301458

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=3.416/5.362
=0.63707572

Malaysian Genomics Resource Centre Bhd's gross margin of this year was 0.71301458. Malaysian Genomics Resource Centre Bhd's gross margin of last year was 0.63707572. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=9.328/21.499
=0.43388065

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=5.362/24.685
=0.21721693

Malaysian Genomics Resource Centre Bhd's asset turnover of this year was 0.43388065. Malaysian Genomics Resource Centre Bhd's asset turnover of last year was 0.21721693. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+1+1+1+1+0+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Malaysian Genomics Resource Centre Bhd has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
Malaysian Genomics Resource Centre Bhd (XKLS:0155) has a Piotroski F-Score of 7 as of Jun. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Malaysian Genomics Resource Centre Bhd and its competitors. This is 75% above median its historical median of 4.00. Over the past decade, Malaysian Genomics Resource Centre Bhd's Piotroski F-Score has ranged from 1.00 to 8.00. According to the industry distribution chart, Malaysian Genomics Resource Centre Bhd ranks #13 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 6.2%.
Is Malaysian Genomics Resource Centre Bhd's Piotroski F-Score too high?
Malaysian Genomics Resource Centre Bhd's current Piotroski F-Score of 7 is 75% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 8.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. Malaysian Genomics Resource Centre Bhd's value of 7 is 40% above this industry median. Based on the distribution chart, Malaysian Genomics Resource Centre Bhd ranks #13 out of 211 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Malaysian Genomics Resource Centre Bhd has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Malaysian Genomics Resource Centre Bhd's Piotroski F-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Malaysian Genomics Resource Centre Bhd ranks #13 out of 211 companies for Piotroski F-Score. This places Malaysian Genomics Resource Centre Bhd in the top 6% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Malaysian Genomics Resource Centre Bhd's value of 7 is 40% above this benchmark. Historically, Malaysian Genomics Resource Centre Bhd's own Piotroski F-Score has ranged from 1.00 to 8.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Malaysian Genomics Resource Centre Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Malaysian Genomics Resource Centre Bhd's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Malaysian Genomics Resource Centre Bhd and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Malaysian Genomics Resource Centre Bhd's current Piotroski F-Score is 7, which is 75% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Malaysian Genomics Resource Centre Bhd stock overvalued right now?
Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd (XKLS:0155) is currently considered Modestly Undervalued. The stock's GF Value™ is RM0.30, compared to a current price of RM0.27 — trading 11.7% below its estimated fair value. The current Piotroski F-Score is 7, which is 75% above median its 10-year median of 4.00 and 40% above the Medical Diagnostics & Research industry median of 5.00. Malaysian Genomics Resource Centre Bhd's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Malaysian Genomics Resource Centre Bhd (XKLS:0155), the current Piotroski F-Score is 7 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Malaysian Genomics Resource Centre Bhd (XKLS:0155) Overvalued in 2026?

Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd stock appears to be undervalued. The current stock price of RM0.27 is trading 11.7% below its estimated GF Value™ of RM0.30. GuruFocus considers Malaysian Genomics Resource Centre Bhd to be Modestly Undervalued.

Key valuation signals for XKLS:0155:

  • Piotroski F-Score: 7 (75% above median its 10-year median of 4.00)
  • GF Value™: RM0.30 vs. price of RM0.27 (11.7% below fair value)
  • GF Score™: 47/100 with 2 warning signs
  • Industry Position: 40% above the Medical Diagnostics & Research median (#13 of 211)

No single metric tells the full story. See the XKLS:0155 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Malaysian Genomics Resource Centre Bhd Business Description

Address Jalan Teknologi 3/6, 8F, Taman Sains Selangor 1, Kota Damansara (PJU5), Petaling Jaya, SGR, MYS, 47810
Malaysian Genomics Resource Centre Bhd is a Malaysia-based company. The company's principal activities include enabling personalized and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services, as well as investment holding. It offers genome sequencing and analysis (GSA) services and genetic screening services (GSS). The group offerings include precision genetic screening, project-based analysis, and high-quality cell therapy and cosmeceutical products. The reportable segments of the Group derive their revenue from the provision of personalised and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services within the healthcare segment.
47GF Score

Get the complete analysis for XKLS:0155

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

RM0.27
Price
RM0.30
GF Value